UPDATE: J.P. Morgan Raises PT on Merck & Co. to $44 (MRK)

J.P. Morgan is out with its report today on Merck & Co. MRK, raising its PT from $42 to $44. In a note to clients, J.P. Morgan writes, "We are increasing our MRK sales and EPS estimates following strong 1Q/11 results. Our new estimates are toward the high end of the company's 2011 guidance range. We are raising our PT by $2 to $44. J.P. Morgan maintains Overweight on MRK. Shares of MRK closed Friday at $35.95, up 0.50% from Thursday's close.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsHealth CareJ.P. MorganMerck & Co.Pharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!